Suchergebnisse

search

Such-Filter

Organisationen
aTyr Pharma, Inc.
Atyr_Logo.png
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27. März 2025 16:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atyr_Logo.png
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
26. März 2025 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
Atyr_Logo.png
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
13. März 2025 16:01 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Atyr_Logo.png
aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine
12. März 2025 16:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine
Atyr_Logo.png
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
06. März 2025 16:02 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
Atyr_Logo.png
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
04. März 2025 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
Atyr_Logo.png
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
24. Februar 2025 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
Atyr_Logo.png
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
29. Januar 2025 08:00 ET | aTyr Pharma, Inc.
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025...
Atyr_Logo.png
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
17. Dezember 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Atyr_Logo.png
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
12. Dezember 2024 16:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors